Latest News Archive
Please select Category, Year, and then Month to display items
07 March 2024
Photo Lunga Luthuli
Prof Francois Strydom, Senior Director at the Centre for Teaching and Learning and Simphiwe Kunene, the first African DREAM scholar and a master’s student from the Faculty of Education.
The University of the Free State (UFS) received recognition for its commitment to student success at the 2024 Achieving the Dream (ATD) conference which celebrated its 20-year anniversary. Simphiwe Kunene, an Education master's student originally from the Qwaqwa campus, was selected to represent South Africa as the first DREAM scholar from Africa as part of the conference.
The Achieving the Dream network of over 300 institutions, which is one of the largest movements in US higher education aims to transform colleges and universities so that students of colour and a lower socio-economic status are supported to earn a degree. The UFS is a leading partner in the Siyaphumelela Network, which has been working for 10 years with ATD to enhance the success of students in South Africa. Prof Francois Strydom, Senior Director at the Centre of Teaching and Learning (CTL), accepted the award on behalf of the institution.
Prof Strydom said that collaboration with the ATD and Siyaphumelela institutions has helped the UFS to develop cutting-edge approaches to “level the playing field” and support Kovsies to earn their undergraduate degrees.
The first African DREAM scholar
Kunene was selected as the first African DREAM scholar from the Siyaphumelela network. To select the DREAM scholar, each Siyaphumelela partner institution nominated one student as a preferred candidate. From the proposed candidates, the DREAM scholar was selected by the South African Institute for Distance Education (Saide) based on the following: demonstrating resilience, academic excellence, and a deep commitment to making a positive difference in universities and personal communities.
He addressed the conference of over 2 000 delegates and shared with them his hopes and dreams. Many members of the South African delegation said Simphiwe did his country proud. He had the following to say about his opportunity to be a DREAM scholar: “Being a DREAM scholar was life changing for me, exposing me to an array of opportunities I never knew were possible and available for me. It was as if, for a moment, the world had stopped to just listen to what I had to say."
The way forward
The UFS will continue its work as a partner of the Siyaphumelela network for the 2024-2026 cycle. The multi-stakeholder project team is focused on enhancing undergraduate students’ time, and to position the UFS as a thought and research leader in the area of student success as part of Vision 130.
New research informs improved treatment of brain inflammation
2017-10-13
Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish
Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology.
Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.
Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs.
Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology